Edition:
United Kingdom

People: Erytech Pharma SA (ERYP.PA)

ERYP.PA on Paris Stock Exchange

5.02EUR
3:33pm BST
Change (% chg)

€0.02 (+0.40%)
Prev Close
€5.00
Open
€5.09
Day's High
€5.09
Day's Low
€4.97
Volume
5,812
Avg. Vol
24,310
52-wk High
€9.13
52-wk Low
€4.52

Kress, Jean-Paul 

Dr. Jean-Paul Kress, M.D. is appointed as Chairman of the Board of the Company, effective June 21, 2019. He was President and Chief Executive Officer and a member of the Board of Directors of Syntimmune from January 2018 until its acquisition by Alexion Pharmaceuticals in November 2018 for up to $1.2 billion. Prior to joining Syntimmune, Dr. Kress served as Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen Inc. Previously, Dr. Kress served as Senior Vice President, Head of North America at Sanofi Genzyme. From July 2011 to September 2015, Dr. Kress served as President and Chief Executive Officer of Sanofi Pasteur MSD, a leading European vaccine company. Prior to this, Dr. Kress worked at Gilead, Abbvie and Eli Lilly in senior commercial and business development roles in the United States and in Europe.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --